stockmarketproxy
/
PTCTNasdaq SEC EDGAR

PTC THERAPEUTICS, INC.

Pharmaceutical Preparations·WARREN, NJ·FY end 12/31·CIK 1070081
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$1.7B$806.8M$937.8M$698.8M$538.6M
Gross Profit——————
Operating Income$866.9M-$302.6M-$439.5M-$447.4M-$374.4M
Net Income$682.6M-$363.3M-$626.6M-$559.0M-$523.9M
Operating CF$711.2M-$107.7M-$158.4M-$356.7M-$251.3M
Capex$8.9M$6.5M$28.4M$32.0M$28.2M
Free Cash Flow$702.3M-$114.2M-$186.9M-$388.7M-$279.5M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin50.1%-37.5%-46.9%-64.0%-69.5%
Net Margin39.4%-45.0%-66.8%-80.0%-97.3%
FCF Margin40.6%-14.2%-19.9%-55.6%-51.9%
R&D / Revenue26.3%66.2%71.1%93.2%100.4%
Effective Tax2.0%-0.0%10.0%4.8%-1.1%
Debt / Equity—-0.26-0.35-1.65196.03
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
PTCT
7:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
PTCT
$23M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
PTCT
39.4%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%